deltatrials
Completed PHASE3 NCT00120757

Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)

Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions HIV Infections Osteoporosis
Interventions Alendronate
Updated 5 times since 2017 Last updated: Dec 21, 2011 Started: Oct 31, 2004 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

A PHASE3 clinical study on HIV Infections and Osteoporosis, this trial is completed. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 5 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • French National Agency for Research on AIDS and Viral Hepatitis
Data source: French National Agency for Research on AIDS and Viral Hepatitis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bobigny, France
  • • Paris, France